SLC47A1P2: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: SLC47A1P2

NCBI ID: G112451549

SLC47A1P2

Other Name(s): SLC47A1 pseudogene 2

SLC47A1P2: A Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant morbidity and disability, making it an attractive target for drug development. The SLC47A1P2 gene, located on chromosome 12, has been identified as a potential drug target and biomarker for chronic pain management. In this article, we will explore the SLC47A1P2 gene, its potential as a drug target, and its potential as a biomarker for chronic pain.

SLC47A1P2 gene

The SLC47A1P2 gene is located on chromosome 12 and encodes a protein known as SLC47A1P2. SLC47A1P2 is a member of the SLC47 family, which includes several structurally similar genes that are involved in the transport of various molecules across cell membranes. The SLC47A1P2 gene is expressed in various tissues and organs, including brain, muscle, and peripheral tissues.

Potential drug target

The SLC47A1P2 gene has been identified as a potential drug target for chronic pain management due to its involvement in the production of norepinephrine, a key neurotransmitter involved in pain modulation. Chronic pain is often associated with increased levels of norepinephrine, which can lead to persistent pain. By targeting the SLC47A1P2 gene, researchers may be able to develop new pain medications that can effectively alleviate chronic pain.

SLC47A1P2 has been shown to play a role in the production of norepinephrine in the brain. Several studies have demonstrated that the levels of SLC47A1P2 gene expression are significantly increased in the brain in individuals with chronic pain. Additionally, knockdown SLC47A1P2 gene expression has been shown to reduce the production of norepinephrine in the brain, providing evidence for the role of SLC47A1P2 in pain modulation.

Biomarker potential

SLC47A1P2 has also been identified as a potential biomarker for chronic pain. The production of norepinephrine is a well-established biomarker for pain, and changes in norepinephrine levels have been shown to be associated with changes in pain perception. By measuring the levels of SLC47A1P2 gene expression in individuals with chronic pain, researchers may be able to develop new diagnostic tools for pain assessment and monitoring.

SLC47A1P2 has also been shown to be involved in the production of other molecules that are involved in pain modulation, including endocannabinoids and inflammatory cytokines. Therefore, measuring the levels of these molecules may also provide valuable information about the role of SLC47A1P2 in pain modulation.

Conclusion

SLC47A1P2 is a gene that has been identified as a potential drug target and biomarker for chronic pain management. Its involvement in the production of norepinephrine, a key neurotransmitter involved in pain modulation, makes it an attractive target for drug development. Additionally, SLC47A1P2 has also been shown to be involved in the production of other molecules that are involved in pain modulation, providing valuable information about its role in pain management. Further research is needed to fully understand the potential of SLC47A1P2 as a drug target and biomarker for chronic pain management.

Protein Name: SLC47A1 Pseudogene 2

The "SLC47A1P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC47A1P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets